Genetic testing has been applied for decades in clinical routine diagnostics of hematological
malignancies to improve disease (sub) classification, prognostication, patient management …

Most patients with advanced malignancies are treated with severely toxic, first-line
chemotherapies. Personalized treatment strategies have led to improved patient outcomes …

Deep single-cell multi-omic profiling offers a promising approach to understand and
overcome drug resistance in relapsed or refractory (rr) acute myeloid leukemia (AML). Here …

Chromosomal instability is a major driver of intratumoral heterogeneity (ITH), promoting
tumor progression. In the present study, we combined structural variant discovery and …

This study aimed to validate the new European Leukemia Net (ELN) 2022 criteria for genetic
risk stratification in older adults with acute myeloid leukemia (AML) and to determine the …

Abstract T-prolymphocytic leukemia (T-PLL) is a mature T-cell neoplasm associated with
marked chemotherapy resistance and continued poor clinical outcomes. Current treatments …

The principle of drug sensitivity testing is to expose cancer cells to a library of different drugs
and measure its effects on cell viability. Recent technological advances, continuous …

COI notes: MK discloses grants and other from AbbVie, grants and other from F. Hoffman La-
Roche, grants and other from Stemline Therapeutics, grants and other from Forty-Seven …

Cancer is still one of the leading causes of death worldwide, despite that tremendous
resources are being invested in drug discovery (Siegel et al., 2022). Recent developments …

Acute myeloid leukemia (AML) is a highly aggressive and heterogeneous disease,
underscoring the need for improved therapeutic options and methods to optimally predict …